Company Overview

Response Genetics, Inc. (OTC: RGDXQ) was a molecular diagnostics company focused on cancer testing and personalized medicine. The company developed and commercialized diagnostic assays intended to help physicians tailor oncology treatments based on a patient’s genetic profile. Its operations were centered on molecular profiling technologies used to evaluate biomarkers associated with chemotherapy response and disease progression, primarily within the oncology sector.

The company’s principal revenue drivers historically included laboratory testing services, biomarker analysis, and companion diagnostic-related activities for cancer care providers and pharmaceutical collaborators. Response Genetics served oncologists, hospitals, clinical laboratories, and biopharmaceutical companies involved in cancer therapeutics development. The company was founded in 2000 and expanded during the growth of precision medicine and pharmacogenomics in oncology. Public filings and market records indicate that the company later experienced financial distress, ultimately entering bankruptcy proceedings, after which its shares traded on the over-the-counter market under the symbol RGDXQ.

Business Operations

Response Genetics operated primarily through its molecular diagnostics laboratory business, with a focus on genetic and biomarker testing for cancer treatment optimization. Its testing portfolio included assays designed to evaluate tumor-specific genetic markers associated with responsiveness to chemotherapy agents and targeted therapies. The company generated revenue through diagnostic testing services reimbursed by healthcare providers and insurers, as well as through research collaborations and laboratory service agreements.

Operations were concentrated in the United States, where the company maintained laboratory and administrative functions. Response Genetics also pursued collaborations with pharmaceutical and biotechnology companies involved in oncology drug development and companion diagnostics. Public disclosures referenced technologies related to PCR-based molecular testing and gene-expression analysis. Data regarding significant active subsidiaries or joint ventures during the company’s final operating years is inconclusive based on available public sources.

Strategic Position & Investments

Response Genetics positioned itself within the emerging personalized oncology diagnostics market, emphasizing the clinical utility of biomarker-driven treatment selection. The company sought growth through expansion of its molecular testing menu, physician adoption of precision medicine approaches, and collaborations tied to oncology drug development. Strategic efforts included participation in companion diagnostics initiatives and clinical research partnerships intended to align diagnostic testing with targeted cancer therapies.

Historically, the company invested in laboratory infrastructure, proprietary testing methodologies, and commercialization activities tied to molecular oncology. Public records indicate that Response Genetics pursued acquisitions and licensing arrangements during its operating history, although available public sources provide limited clarity regarding the long-term strategic impact of those transactions. The company operated in a highly competitive diagnostics environment that included larger clinical laboratory operators and specialized molecular diagnostics firms.

Geographic Footprint

Response Genetics’ operational footprint was primarily concentrated in the United States, with headquarters historically located in California. The company’s laboratory testing and commercial activities focused mainly on the U.S. healthcare and oncology markets, where it served physicians, hospitals, and cancer treatment centers.

Although the company’s core business was domestic, its testing and pharmaceutical collaboration activities had relevance to broader international oncology research and precision medicine trends. Publicly available information does not indicate a substantial standalone operational presence across multiple continents. Data regarding extensive international subsidiaries or direct overseas laboratory operations is inconclusive based on available public sources.

Leadership & Governance

Response Genetics was founded by Dr. Peter Danenberg, whose research in molecular oncology and pharmacogenomics influenced the company’s scientific direction. Leadership emphasized the use of genetic profiling to improve cancer treatment selection and support personalized medicine initiatives in clinical oncology.

Key executives and leaders associated with the company during its public operating history included:

• Thomas J. Lynch – Chairman and Chief Executive Officer
• Dr. Peter Danenberg – Founder and Chief Scientific Officer
• Rochelle Chasen – Chief Financial Officer
• Kenneth A. Berlin – Director and Executive Chairman during portions of the company’s public history

Corporate governance and operational oversight were conducted through a publicly traded corporate structure subject to reporting obligations under SEC filings, including annual and quarterly disclosures. Available public records indicate that leadership faced significant operational and financial challenges in the company’s later years, culminating in bankruptcy-related proceedings and OTC market trading status under RGDXQ.